WAVEMAN · COMPANY

NNNN · Anbio Biotechnology

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

NNNN

Name: Anbio Biotechnology (NNNN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Anbio Biotechnology

PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0001982708

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+5.6%

XBRL, annual

NET MARGIN

74.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

8 funds added or opened last quarter

below 89% of Pharma & Biotech

REVENUE

+5.6% year over year

more than 55% of Pharma & Biotech

MARGIN

74.1% net margin

more than 97% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

1.2 days to cover · settled 2026-07-31

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 8 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Anbio Biotechnology in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

GEODE CAPITAL MANAGEMENT, LLC

26,736.0 sh

$366.6K

BANK OF AMERICA CORP /DE/

13,419.0 sh

$184.0K

BNP PARIBAS FINANCIAL MARKETS

11,800.0 sh

$161.8K

MARSHALL WACE, LLP

11,502.0 sh

$157.7K

MORGAN STANLEY

7,231.0 sh

$99.1K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$8.6M	$8.2M	$6.7M	$23.5M
GROSS PROFIT	$7.5M	$5.9M	$3.4M	$12.6M
OPERATING INCOME	$5.8M	$2.0M	$2.0M	$10.2M
NET INCOME	$6.4M	$2.4M	$2.3M	$10.0M
EPS (DILUTED)	0.15	0.06	0.10	100,112.00
OPERATING CASH FLOW	$-6.7M	$2.1M	$898.4K	$4.4M
CASH	$7.8M	$11.8M	$9.7M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE